Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04601974
Other study ID # 18/0202
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2024
Est. completion date September 2032

Study information

Verified date May 2023
Source University College, London
Contact Senior Clinical Project Manager
Phone +44(0)2031088954
Email ekctrial@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I/IIa clinical trial investigating the safety of a lentiviral epilepsy gene therapy using an engineered potassium channel in patients with refractory epilepsy.


Description:

Epilepsy affects about 1% of the population. One third of affected individuals continue to have seizures despite optimal medication. The only realistic prospect of seizure freedom, feasible in very few cases, is surgery to remove the brain area where seizures arise. Patients with refractory neocortical epilepsy who are being evaluated for surgical resection of the seizure focus will be invited to join the trial. The non-integrating lentiviral vector, which has been engineered to deliver an engineered potassium channel, will be administered via intracerebral infusion to the area scheduled for resection. The primary objective in this study is to test the safety of the lentiviral gene therapy treatment, including the surgical procedures required for vector administration. Secondary objectives will look at delayed onset adverse events and indicators of efficacy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date September 2032
Est. primary completion date September 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: SCREENING/PRE-CONSENT: 1. Female and male patients with refractory focal epilepsy 2. Aged = 18 years (no upper age limit but deemed medically fit for surgery with a life expectancy of at least 5 years) 3. Patient lives within 1 hour of transfer to an acute neurosurgical unit 4. Being considered for resective brain surgery (to remove the epileptogenic focus) based on first-stage preoperative assessments carried out as part of routine clinical care within 2 years of registration, showing: 4.1. Absence of vascular brain lesions or vascular malformations and/or cancer in the resection area (as confirmed on MRI) 4.2. Absence of active, untreated psychiatric disease in the opinion of the treating clinician (as confirmed by neuropsychiatric assessment) 4.3. Patient requires second-stage intracranial EEG investigations to be carried out via burr hole surgery to further assess eligibility for resective brain surgery PRE-REGISTRATION: 5. Patient deemed clinically suitable for resective brain surgery (i.e. a single region of seizure onset in the neocortex has been identified, and it does not overlap with areas necessary for critical functions such as language), as confirmed by intracranial EEG investigations 6. Patients who are women of childbearing potential (WOCBP), or male patients with female partners who are WOCBP or pregnant must agree to use highly effective methods of contraception from the time consent is signed until three months after treatment. Men (if applicable), must also advise their female partners regarding contraceptive requirements as listed for female patients who are WOCBP or pregnant. 7. Able and willing to give written informed consent to join trial Exclusion Criteria: 1. Not deemed clinically suitable for resective brain surgery (e.g. because of failure to identify a single region of seizure onset in the neocortex, region is too extensive or the region overlaps with areas necessary for critical functions such as language), as confirmed by intracranial EEG investigations 2. Vascular brain lesions or vascular malformations in area of planned resection 3. Detection of active cancer or on systemic treatment for cancer 4. Known or suspected HIV infection (confirmed by PCR test) and/or taking antiretroviral therapy 5. Patient deemed medically unfit for anaesthesia and surgery 6. Active, untreated psychiatric disease in the opinion of the treating clinician 7. Concurrent and/or recent involvement in another clinical trial of an investigational medicinal product (within last 3 months) 8. Females who are pregnant (confirmed by serum/urine ß-HCG) or actively breast-feeding 9. Known allergies to excipients of lentiviral gene therapy 10. Patient unlikely to cooperate with a 5-year follow-up; medical or psychological condition at the discretion of the investigator which would not permit compliance with the protocol or meaningful written informed consent 11. Any other known condition which is assessed as an intolerable risk by the investigator upon inclusion in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
lentiviral gene therapy
lentiviral gene therapy to treat drug resistant epilepsy

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University College, London Medical Research Council

Outcome

Type Measure Description Time frame Safety issue
Primary Safety during the First Year (for adverse events related to lentiviral gene therapy only) Number and severity of all adverse events (graded using CTCAE v5.0) in patients deemed causally related to lentiviral gene therapy At 6 weeks, 3 months, 6 months and 12 months after trial treatment
Primary Safety during the First Year (for adverse events causally related to investigational surgical procedures only) Number and severity of all adverse events (graded using CTCAE v5.0) deemed causally related to any of the investigational surgical trial procedures required for vector administration At 6 weeks, 3 months, 6 months and 12 months after trial treatment
Secondary Long-Term Safety (for adverse events related to lentiviral gene therapy only) Number of serious adverse events (graded using CTCAE v5.0) in patients related to the lentiviral gene therapy From 1 to 5 years after treatment
Secondary Long-Term Safety (for adverse events causally related to investigational surgical procedures only) Number of serious adverse events (graded using CTCAE v5.0) in patients related to the investigational surgical procedures required for vector administration From 1 to 5 years after treatment
Secondary Clinical Indicators of Efficacy and Tolerability Seizure frequency and severity over preceeding 4 weeks Measured at 6 weeks, 3 months, 6 months, and 12 months/1 year after trial treatment
Secondary Clinical Indicators of Efficacy and Tolerability Seizure frequency and severity (using IALE outcomes scale) Measured at 12 months/1 year, 2 years, 3 years, 4 years and 5 years after trial treatment
Secondary Clinical Indicators of Efficacy and Tolerability Proportion of patients who have had surgical resection at 3, 6, or 12 months, or at 2, 3, 4, and 5 years after trial treatment
Secondary Cortical excitability Cortical excitability (assessed using TMS, EMG, and high-density EEG) at 6 months after trial treatment (only for patients in TMS study)
See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05928598 - Goals for Epilepsy Clinic Visits Trial N/A
Recruiting NCT05539287 - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Phase 2
Completed NCT02982824 - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy N/A
Recruiting NCT05485558 - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy Phase 2
Not yet recruiting NCT04553354 - Cortical Resections in Drug Resistant Epilepsy
Recruiting NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy N/A
Recruiting NCT04714996 - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy Phase 2
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Recruiting NCT06059157 - Epileptogenic Network Visualisation With Advanced MRI N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Recruiting NCT05393518 - Electroclinical Correlation of Anxiety N/A
Not yet recruiting NCT05555537 - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed NCT03419000 - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY N/A
Enrolling by invitation NCT06341075 - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy N/A
Not yet recruiting NCT05527093 - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy N/A
Recruiting NCT05697614 - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children Phase 4
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT06432907 - StereoEEG Motor Neuronal Potentials Decoding N/A
Not yet recruiting NCT06340802 - A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl N/A